Haleon (HLN) EBT Margin (2021 - 2023)

Haleon (HLN) recorded quarterly EBT Margin of 17.73% in Q4 2023, up 16.71% on a QoQ basis from 15.19% in Q2 2023, and down 112.0% year-over-year from 147.72% in Q4 2022.

Haleon (HLN) EBT Margin (2021 - 2023) Analysis & Trends

Haleon has disclosed EBT Margin across 3 years of filings, most recently posting 17.73% for Q4 2023.

  • Quarterly EBT Margin fell 112.0% year-over-year to 17.73% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 17.45% (changed N/A YoY) and the FY2025 annual result came in at 19.51%, up 251.0% from the prior year.
  • EBT Margin advanced to 17.73% in Q4 2023, from 15.19% in the prior quarter.
  • Over five years, EBT Margin peaked at 20.36% in Q4 2021 and troughed at 15.19% in Q2 2023.
  • A 3-year average of 18.05% and a median of 18.15% in 2023 frame the typical range for EBT Margin.
  • Annual changes were most pronounced in 2022 — EBT Margin sank 152 bps — and 2023, when it slumped 112 bps.
  • Tracing HLN's EBT Margin over 3 years: stood at 20.36% in 2021, then declined by 7 bps to 18.84% in 2022, then declined by 6 bps to 17.73% in 2023.
  • Business Quant data shows HLN's EBT Margin at 17.73% in Q4 2023, 15.19% in Q2 2023, and 18.15% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 10.97%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 33.51%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 40.73%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 25.87%
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 30.30%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 6.35%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -156.77%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -16.70%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 41.45%
10 Haleon 1.09 Bn -773.69 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 17.73%
Jun 30, 2023 15.19%
May 3, 2023 18.15%
Dec 31, 2022 18.84%
Dec 31, 2021 20.36%